Edgar Filing: ANTIGENICS INC /DE/ - Form 4

| ANTIGENICS I | NC /DE/ | | | | | | | | | | |
|--|--|---|--|-------------------------------|---------------------------------------|---|--|---|---------------------------------------|---|------|
| Form 4 May 17, 2010 | | | | | | | | | | | |
| • | 1 | | | | | | | | | PPROVA | L |
| | FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | N OMB Number: | 3235-(| 0287 |
| Check this be if no longer subject to Section 16. Form 4 or Form 5 obligations may continue See Instruction 1(b). | STATEM Filed pur Section 17(| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | January 31, 2005Expires:2005Estimated average burden hours per response0.5 | |
| (Print or Type Resp | onses) | | | | | | | | | | |
| 1. Name and Addro DECHAENE T | | Person <u>*</u> | Symbol | er Name an GENICS 1 | | | C | 5. Relationship o Issuer | of Reporting Per eck all applicabl | | |
| (Last) (First) (Middle) C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900 | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/13/2010 | | | | | X_Director10% Owner Officer (give titleOther (specify below) below) | | | |
| (Street) | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting | | | | | |
| NEW YORK, N | NY 10010 | | | | | | | Person | More than one R | eporting | |
| (City) | (State) | (Zip) | Tab | ole I - Non- | Deriva | tive S | ecurities A | Acquired, Disposed | of, or Beneficia | lly Owned | 1 |
| | ransaction Date nth/Day/Year) | 2A. Deeme Execution any (Month/Da | Date, if TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or | | A) or f (D) and 5) (A) or | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature Indirect Beneficial Ownershi (Instr. 4) | 1 | | |
| Domindon Donort | n o concrete line | for each al | and of and | | | | | | | | |
| Reminder: Report of | n a separate line | or each cla | ass of sec | | Pe inf rec dis | erson forma quire | s who res ation cont d to resp vs a curre | or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co | n are not rm | SEC 1474 (9-02) | |

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. Number of | 6. Date Exercisable and | 7. Title and Amount o |
|-------------|-------------|---------------------|--------------------|-----------|--------------|-------------------------|-----------------------|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transacti | orDerivative | Expiration Date | Underlying Securities |
| Security | or Exercise | | any | Code | Securities | (Month/Day/Year) | (Instr. 3 and 4) |

Edgar Filing: ANTIGENICS INC /DE/ - Form 4

| (Instr. 3) | Price of Derivative Security | (Mor | nth/Day/Year) | (Instr. | 8) | Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | | | | |
|--------------------------------------|------------------------------------|------------|---------------|---------|----|--|-----|-----------------------|--------------------|-----------------|------------------------------------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Share |
| Stock Option (right to buy) | \$ 1.24 | 05/13/2010 | | А | | 15,000 | | 05/13/2011 <u>(1)</u> | 05/13/2020 | Common Stock | 15,000 |

Reporting Owners

| Reporting Owner Name / Address | | Relationsh | | |
|--|----------|------------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| DECHAENE TOM C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK, NY 10010 | Х | | | |
| Signatures | | | | |
| Christine M. Klaskin, by Power of Attorney | | 05/17/20 | 010 | |
| **Signature of Reporting Person | | Date | | |
| Explanation of Poen | onco | . . | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Options vest in three equal annual installments beginning May 13, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. style="border:none">If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).(1)Grant of non-qualified options which will vest in three equal annual installments on the last day of the company's fiscal year, beginning in 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.